Utilization of healthcare services in acute myocardial
infarction and the risk of out-of-hospital cardiac death

J 2024

Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death

MOTOVSKA, Zuzana; Ota HLINOMAZ; Milan HROMADKA; Jan MROZEK; Jan PRECEK et. al.

Základní údaje

Originální název

Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death

Autoři

Vydání

Panminerva medica, TURIN, EDIZIONI MINERVA MEDICA, 2024, 0031-0808

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.300 v roce 2022

Kód RIV

RIV/00216224:14110/24:00135366

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.23736/S0031-0808.23.04910-8

UT WoS

001146442100001

EID Scopus

2-s2.0-85187724770

Klíčová slova anglicky

bone marrow fibrosis; momelotinib; ruxolitinib

Štítky

14110115, 14110132, 14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 1. 2025 13:12, Mgr. Tereza Miškechová

Anotace

V originále

Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor–naive patients from SIMPLIFY-1 (NCT01969838), a double-blind, randomized, phase 3 study of momelotinib vs ruxolitinib. Baseline and week 24 bone marrow biopsies were graded from 0 to 3 as per World Health Organization criteria. Other assessments included Total Symptom Score, spleen volume, transfusion independence status, and hemoglobin levels. Paired samples were available from 144 and 160 patients randomized to momelotinib and ruxolitinib. With momelotinib and ruxolitinib, transfusion independence was achieved by 87% and 44% of patients with BMF improvement of ≥1 grade and 76% and 56% of those with stable/worsening BMF; there was no association between BMF changes and transfusion independence for either arm (momelotinib, p = .350; ruxolitinib, p = .096). Regardless of BMF changes, hemoglobin levels also generally increased on momelotinib but decreased on ruxolitinib. In addition, no associations between BMF changes and spleen (momelotinib, p = .126; ruxolitinib, p = .407)/symptom (momelotinib, p = .617; ruxolitinib, p = .833) outcomes were noted, and no improvement in overall survival was observed with ≥1-grade BMF improvement (momelotinib, p = .395; ruxolitinib, p = .407). These data suggest that the anemia benefit of momelotinib is not linked to BMF changes, and question the use of BMF assessment as a surrogate marker for clinical benefit with JAK inhibitors.

Návaznosti

LM2023049, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network

LX22NPO5104, projekt VaV

Název: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Akronym: CarDia)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní institut pro léčbu metabolických a kardiovaskulárních onemocnění, 5.1 EXCELES

NV19-02-00086, projekt VaV

Název: Duální protidestičková léčba pacientů s akutním infarktem myokardu v kardiogenním šoku - studie DAPT-SHOCK AMI

Investor: Ministerstvo zdravotnictví ČR, Duální protidestičková léčba pacientů s akutním infarktem myokardu v kardiogenním šoku - studie DAPT-SHOCK AMI

Přiložené soubory

Utilization_of_healthcare_services_in_acute_myocardial_infarction_and_the_risk_of_out-of-hospital_cardiac_death.pdf

Citovat

MOTOVSKA, Zuzana; Ota HLINOMAZ; Milan HROMADKA; Jan MROZEK; Jan PRECEK; Petr KALA; Tamilla MUZAFAROVA; Jiri KETTNER; Jan MATEJKA; Josef BIS; Pavel CERVINKA; Pavol TOMASOV; Anna KLECHOVA; Ondřej ŠANCA a Jiří JARKOVSKÝ. Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death. Panminerva medica. TURIN: EDIZIONI MINERVA MEDICA, 2024, roč. 66, č. 1, s. 79-81. ISSN 0031-0808. Dostupné z: https://doi.org/10.23736/S0031-0808.23.04910-8.

@article{2362484,
   author = {Motovska, Zuzana and Hlinomaz, Ota and Hromadka, Milan and Mrozek, Jan and Precek, Jan and Kala, Petr and Muzafarova, Tamilla and Kettner, Jiri and Matejka, Jan and Bis, Josef and Cervinka, Pavel and Tomasov, Pavol and Klechova, Anna and Šanca, Ondřej and Jarkovský, Jiří},
   article_location = {TURIN},
   article_number = {1},
   doi = {https://doi.org/10.23736/S0031-0808.23.04910-8},
   keywords = {bone marrow fibrosis; momelotinib; ruxolitinib},
   language = {eng},
   issn = {0031-0808},
   journal = {Panminerva medica},
   title = {Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death},
   url = {https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y9999N00A23080302},
   volume = {66},
   year = {2024}
}

TY  - JOUR
ID  - 2362484
AU  - Motovska, Zuzana - Hlinomaz, Ota - Hromadka, Milan - Mrozek, Jan - Precek, Jan - Kala, Petr - Muzafarova, Tamilla - Kettner, Jiri - Matejka, Jan - Bis, Josef - Cervinka, Pavel - Tomasov, Pavol - Klechova, Anna - Šanca, Ondřej - Jarkovský, Jiří
PY  - 2024
TI  - Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death
JF  - Panminerva medica
VL  - 66
IS  - 1
SP  - 79-81
EP  - 79-81
PB  - EDIZIONI MINERVA MEDICA
SN  - 00310808
KW  - bone marrow fibrosis
KW  - momelotinib
KW  - ruxolitinib
UR  - https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y9999N00A23080302
N2  - Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor–naive patients from SIMPLIFY-1 (NCT01969838), a double-blind, randomized, phase 3 study of momelotinib vs ruxolitinib. Baseline and week 24 bone marrow biopsies were graded from 0 to 3 as per World Health Organization criteria. Other assessments included Total Symptom Score, spleen volume, transfusion independence status, and hemoglobin levels. Paired samples were available from 144 and 160 patients randomized to momelotinib and ruxolitinib. With momelotinib and ruxolitinib, transfusion independence was achieved by 87% and 44% of patients with BMF improvement of ≥1 grade and 76% and 56% of those with stable/worsening BMF; there was no association between BMF changes and transfusion independence for either arm (momelotinib, p = .350; ruxolitinib, p = .096). Regardless of BMF changes, hemoglobin levels also generally increased on momelotinib but decreased on ruxolitinib. In addition, no associations between BMF changes and spleen (momelotinib, p = .126; ruxolitinib, p = .407)/symptom (momelotinib, p = .617; ruxolitinib, p = .833) outcomes were noted, and no improvement in overall survival was observed with ≥1-grade BMF improvement (momelotinib, p = .395; ruxolitinib, p = .407). These data suggest that the anemia benefit of momelotinib is not linked to BMF changes, and question the use of BMF assessment as a surrogate marker for clinical benefit with JAK inhibitors.
ER  -

MOTOVSKA, Zuzana; Ota HLINOMAZ; Milan HROMADKA; Jan MROZEK; Jan PRECEK; Petr KALA; Tamilla MUZAFAROVA; Jiri KETTNER; Jan MATEJKA; Josef BIS; Pavel CERVINKA; Pavol TOMASOV; Anna KLECHOVA; Ondřej ŠANCA a Jiří JARKOVSKÝ. Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death. \textit{Panminerva medica}. TURIN: EDIZIONI MINERVA MEDICA, 2024, roč.~66, č.~1, s.~79-81. ISSN~0031-0808. Dostupné z: https://doi.org/10.23736/S0031-0808.23.04910-8.

Přehled o publikaci